Inebilizumab has received import and marketing permission in Taiwan for Neuromyelitis Optica Spectrum Disorder
October 17, 2022
Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Hiroaki Ueno; hereinafter, “MTPC”), a member of the Mitsubishi Chemical Group, announced today that Tai Tien Pharmaceuticals Co., Ltd. (Head Office: Taipei, Taiwan; General Manager Tony Chu; hereinafter, “Tai Tien”), which is a consolidated subsidiary of MTPC, has received import and marketing permission for UPLIZNA® for Intravenous Infusion 100mg (UPLIZNA, generic name: inebilizumab (genetically modified), Japanese name: UPLIZNA® for I.V. Infusion 100mg) as a treatment agent for neuromyelitis optica spectrum disorder (NMOSD) in Taiwan on September 30, 2022.
In Taiwan, NMOSD was designated as a rare disease in November 2021. UPLIZNA has not only a new mechanism of action for NMOSD, but also a convenient dosing interval of once every six months, that enables treatment tailored to the lifestyle of patients. Tai Tien will strengthen its business base through further expansion of the product lineup in the central nervous system disease area and offer UPLIZNA as a new treatment option for NMOSD patients in the relapse prevention period.
MTPC in-licensed this drug from Horizon Therapeutics plc (Head Office: Dublin, Ireland; hereinafter, “Horizon”) and has received approval for the treatment of NMOSD in Japan and South Korea. In addition, MTPC, in collaboration with Horizon, is conducting phase 3 clinical studies globally, including in Japan, for myasthenia gravis and IgG4-related disease.
MTPC will continue to contribute to improving the quality of life of patients by delivering treatment options to patients fighting against NMOSD.
About UPLIZNA
UPLIZNA is a humanized anti-CD19 monoclonal antibody. It binds to a protein called CD19 which is expressed on B cells including antibody-producing plasmablasts and plasma cells, and rapidly depletes these cells from circulation. For the treatment of NMOSD, Horizon has received approval for UPLIZNA in the US and EU, and its partner has received approval in China.
About Tai Tien Pharmaceuticals Co., Ltd. (Tai Tien)
Tai Tien Pharmaceuticals was established in Taipei in 1987 and marketed various products including HERBESSER®, CONCOR® (Japanese name: MAINTATE®), and LIVALO®. With the launch of CANAGLU®, Tai Tien is contributing to the treatment of patients with type 2 diabetes in Taiwan by leveraging the foundation of its core therapeutic area for lifestyle-related diseases.
In Taiwan, NMOSD was designated as a rare disease in November 2021. UPLIZNA has not only a new mechanism of action for NMOSD, but also a convenient dosing interval of once every six months, that enables treatment tailored to the lifestyle of patients. Tai Tien will strengthen its business base through further expansion of the product lineup in the central nervous system disease area and offer UPLIZNA as a new treatment option for NMOSD patients in the relapse prevention period.
MTPC in-licensed this drug from Horizon Therapeutics plc (Head Office: Dublin, Ireland; hereinafter, “Horizon”) and has received approval for the treatment of NMOSD in Japan and South Korea. In addition, MTPC, in collaboration with Horizon, is conducting phase 3 clinical studies globally, including in Japan, for myasthenia gravis and IgG4-related disease.
MTPC will continue to contribute to improving the quality of life of patients by delivering treatment options to patients fighting against NMOSD.
About UPLIZNA
UPLIZNA is a humanized anti-CD19 monoclonal antibody. It binds to a protein called CD19 which is expressed on B cells including antibody-producing plasmablasts and plasma cells, and rapidly depletes these cells from circulation. For the treatment of NMOSD, Horizon has received approval for UPLIZNA in the US and EU, and its partner has received approval in China.
About Tai Tien Pharmaceuticals Co., Ltd. (Tai Tien)
Tai Tien Pharmaceuticals was established in Taipei in 1987 and marketed various products including HERBESSER®, CONCOR® (Japanese name: MAINTATE®), and LIVALO®. With the launch of CANAGLU®, Tai Tien is contributing to the treatment of patients with type 2 diabetes in Taiwan by leveraging the foundation of its core therapeutic area for lifestyle-related diseases.
